Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CPN1 | P15169 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8957450 | 0.78 | — | — | |
| SCHEMBL8260874 | 0.77 | TDP1 (0.36) | CPN1CPB2MMP2MMP9SLC6A1 | |
| SCHEMBL8957322 | 0.77 | CCNA2 (0.41) | KMT2AMMP2MMP9LMNA | |
| SCHEMBL23829716 | 0.74 | — | — | |
| SCHEMBL9875012 | 0.74 | ALDH1A1 (0.40) | MMP2MMP9TSHR | |
| SCHEMBL6438537 | 0.74 | ALDH1A1 (0.40) | MMP2MMP9TSHR | |
| Nitric Acid SCHEMBL9344153 | 0.73 | TDP1 (0.33) | CPN1CPB2MMP2MMP9SLC6A1 | |
| SCHEMBL3444600 | 0.71 | SCN9A (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CPN1 | |
| SCHEMBL28863484 | 0.71 | SCN9A (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CPN1 | |
| SCHEMBL28241589 | 0.71 | SCN9A (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665472-B1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LTD (IE) | 2022-07-06 | — | — | EP | disclosed |
| EP-2665472-B1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LTD (IE) | 2022-07-06 | — | — | EP | disclosed |
| US-9566342-B2 | Compounds for treatment of heart failure | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2017-02-14 | — | — | US | disclosed |
| US-9566342-B2 | Compounds for treatment of heart failure | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2017-02-14 | — | — | US | disclosed |
| US-9566342-B2 | Compounds for treatment of heart failure | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2017-02-14 | — | — | US | disclosed |
| US-20130338118-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2013-12-19 | — | — | US | disclosed |
| EP-2665472-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | Solvotrin Innovations Limited (IE) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012076667-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2012-06-14 | — | — | WO | disclosed |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1673384-A4 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1673384-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030135-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338118-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | MMP9, NOS2, MMP1 | CHRNB2 4116/4885CHRNA4 4601/4885CHRNB4 4504/4885 |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | GLS, NOS2, NOS1 | CHRNB2 1475/4885CHRNA4 1487/4885CHRNB4 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.